Peficitinib (hydrobromide)

Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].

Product Specifications

CAS Number

[1353219-05-2]

Product Name Alternative

ASP015K (hydrobromide) ; JNJ-54781532 (hydrobromide)

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/peficitinib-hydrobromide.html

Solubility

10 mM in DMSO

Smiles

O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O.Br[H]

Molecular Formula

C18H23BrN4O2

Molecular Weight

407.30

References & Citations

[1]Ito M, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017 Jan;133 (1) :25-33.